MedTrace Logo

Assays for and Reversal of New Anticoagulants

NCT01795781 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2013-05-03

No results posted yet for this study

Summary

New anticoagulants are being introduced to replace warfarin. These drugs do not require monitoring and are safer. There is currently no recommended way to reverse these drugs rapidly in the event of undue bleeding or need for emergency surgery. This is a lab study to look at ways to reverse the drugs rapidly

Conditions

Sponsors & Collaborators

  • R.P.Herrmann

    lead OTHER

Principal Investigators

  • Ross I Baker, MB, BS · Royal Perth Hospital, Wellington St, Perth, Australia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01795781 on ClinicalTrials.gov